Fate Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $4 to $6.
Portfolio Pulse from Benzinga Newsdesk
Fate Therapeutics shares are trading higher following an upgrade from Piper Sandler, which raised the stock rating from Neutral to Overweight and increased the price target from $4 to $6.
June 17, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fate Therapeutics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $4 to $6.
The upgrade from Piper Sandler to Overweight and the increase in the price target from $4 to $6 is a strong positive signal for investors, likely leading to increased buying activity and a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100